Related references
Note: Only part of the references are listed.Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study
Kun Liu et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2022)
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel et al.
OPHTHALMOLOGY (2020)
Faricimab: expanding horizon beyond VEGF
Ashish Sharma et al.
EYE (2020)
Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases
Ivan Seah et al.
EYE (2020)
Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration
Quan Dong Nguyen et al.
OPHTHALMOLOGY (2020)
Is This a 737 Max Moment for Brolucizumab?
Philip J. Rosenfeld et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2020)
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study
Kun Liu et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema BOULEVARD Phase 2 Randomized Trial
Jayashree Sahni et al.
OPHTHALMOLOGY (2019)
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration Results from the Randomized Phase 2 Ladder Clinical Trial
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2019)
COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE
Maximilian Weiss et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema
Catherine Egan et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2017)
Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1)
Kevin J. Blinder et al.
CLINICAL OPHTHALMOLOGY (2017)
Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration
Frank G. Holz et al.
OPHTHALMOLOGY (2016)
Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion 52-Week Results of the VIBRANT Study
W. Lloyd Clark et al.
OPHTHALMOLOGY (2016)
Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
Sobha Sivaprasad et al.
CLINICAL OPHTHALMOLOGY (2016)
United States comparative costs and absenteeism of diabetic ophthalmic conditions
Richard A. Brook et al.
POSTGRADUATE MEDICINE (2015)
Global estimates of diabetes prevalence for 2013 and projections for 2035
L. Guariguata et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema
David S. Boyer et al.
OPHTHALMOLOGY (2014)
Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Joanne W. Y. Yau et al.
DIABETES CARE (2012)
Ranibizumab for Diabetic Macular Edema Results from 2 Phase III Randomized Trials: RISE and RIDE
Quan Dong Nguyen et al.
OPHTHALMOLOGY (2012)
Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2012)
Pericyte Requirement for Anti-Leak Action of Angiopoietin-1 and Vascular Remodeling in Sustained Inflammation
Jonas Fuxe et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
The RESTORE Study Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema
Paul Mitchell et al.
OPHTHALMOLOGY (2011)
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)
Pascale Massin et al.
DIABETES CARE (2010)
Share Paper
